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Introduction 
Pseudomonas putida, an aerobic, glucose-non-fermenting, 
Gram-negative bacillus, is regarded as a ubiquitous 
environmental contaminant that is recovered occasionally 
from clinical specimens. Over the past decade, this species 
has been increasingly recognized as a nosocomial pathogen. 
None of the previously reported clinical isolates of P. putida 
species were characterized as mucoid strains. The present 
case report describes a case of pneumonia caused by a 
mucoid variant of P. putida. 
Case Report 
A 57-year-old woman had been treated for bronchiectasis 
at the Outpatient Clinic of Mitoyo General Hospital, Japan 
(public general hospital, 415 beds) since 1990. She came to 
the Outpatient Clinic because of an increase in the volume 
and purulent nature of the sputum and mild haemoptysis 
on 21 February 1996. She was a non-smoker and had a past 
history of recurrent pneumonia from 1987. Physical exami- 
nation revealed a febrile (temperature 38,O”C) woman with 
a pulse rate of 90 beats min- I, blood pressure of 130/ 
80 mmHg, respiratory rate of 20 breaths min - ’ and coarse 
moist rales over the lower area of both lungs. Her chest 
radiograph and chest computerized tomographic (CT) scan 
showed an infiltrate in the right lower lobe (Plates 1 and 2). 
According to the criteria described by Gudbjerg (l)), her 
chest radiograph was diagnosed to have the honey-comb 
like structures in right middle lobe, right lower lobe and left 
lingula. Her pulmonary function test showed percent vital 
capacity and percent forced expiratory volume (1.0) were 
60.2 and 58.9%, respectively. There was no pleural effusion 
or cavitation. The diagnosis was right lower lobe pneumo- 
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nia, and the patient was admitted to the Mitoyo General 
Hospital. 
The leukocyte count upon admission was 8.2 x 1091- ‘, 
with 75.5% segmented neutrophils, 55% lymphocytes, 4% 
monocytes and 3.5% eosinophils. The patient was treated 
empirically with ceftazidime (1 g twice a day) for 3 days, but 
chest radiograph on Day 4 showed little improvement. 
Sputum cultures at the time of admission and after the 3 
days of ceftazidime treatment yielded mucoid P. putida. No 
other organism was cultured in both episodes. Treatment 
with minocycline (100 mg twice a day), to which the isolates 
were susceptible, was added from Day 4. With this therapy, 
sputum culture on Day 11 yielded no pathogenic bacteria, 
and no infiltrative shadow was seen on the chest radiograph 
on Day 14. She was discharged on Day 24 (8 April 1995). 
There was no significant increase of antibodies against 
Mycoplasma pneumoniae, Legionella pneumophilia and 
Chlamydia pneumoniae. 
Microbiological Studies 
Sputum gram stains revealed 10% intracellular Gram- 
negative bacilli in neutrophils and 3% squamous epithelial 
cells per high-power field. Culture results yielded 
semi-transparent, mucoid and slightly haemolytic colonies 
on sheep blood agar. 
The organism was identified as P. putida by the API 20 
NE system (API System S. A.) (P. putida >97.4% prob- 
ability; profile code, 0140055). In addition, the organism has 
characteristics as follows: fluorescent pigment (f), oxidase 
reaction (+), arginine dihydrolast (+), growth at 42°C ( - ), 
gelatin liquefaction ( - ) and lecithinase (egg yolk) ( - ). 
Antibiotic susceptibility testing was performed by a 
previously described microtitre dilution method. The range 
of antibiotic concentrations utilized varied from 0.5 to 
>64pg ml - ‘. Mueller-Hinton was used as the test medium. 
Organisms (lo5 ml) were inoculated into broth cultures 
and incubated at 37°C for 18 h. The minimal inhibitory 
concentration was defined as the lowest concentration of 
antimicrobial agent resulting in the inhibition of bacterial 
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PLATE 1. Chest X-ray film on the day of admission. 
growth after 18-24 h of incubation at 37°C. Broth 
dilution susceptibility testing demonstrated the following 
results: minocycline MIC, 4 pg ml - ‘; levofloxacin MIC, 
2 ,ug ml - ‘; sparfloxacin MIC, 1 pg ml - ‘; tosufloxacin 
MIC, 1 pug ml - i; piperacillin MIC, ~0.5 pg ml - ‘; ceftazi- 
dime MIC, ~0.5 pug ml- ‘; cefotiam MIC, >64 pg ml - I; 
imipenem MIC, ~0.5 pug ml ~ ‘; latamoxef MIC, 1 pg ml - I; 
carumonam MIC, ~0.5 pug ml ~ ‘; tobramycin MIC, 
>64pgml11; and amikacin MIC, >64 pg ml ~ ‘. 
Discussion 
The authors believe that the present case was primary lung 
infection caused by mucoid P. putida, because sputum 
culture on admission exhibited pure and heavy growth of 
mucoid P. putida, and numerous neutrophils which had 
phagocytized the organism were observed on microscopic 
examination of sputum smears. 
Pseudomonas putida a common inhabitant of soil, water 
and plants, and is isolated from the hospital environment. It 
is part of the normal oropharyngeal flora (2). It is usually 
regarded as an environmental contaminant, but unanimity 
as to its pathogenic significance has been lacking (2). The 
pathogenicity of a closely related organism, P. JEuorescens, 
in cold-blooded animals, and the association of both organ- 
isms with bacteraemia transmitted by contaminated 
PLATE 2. Chest computerized tomographic (CT) scan on 
the day of admission. 
blood products stored at 4°C suggest a facilitating role of 
hypothermia in the pathogenicity of P. putida (3-5). 
Pseudomonas putida has emerged as an occasional bac- 
terial pathogen in immunocompromised patients, and is 
probably related to the increased use of central venous 
catheters (6). Physicians caring for such patients should not 
disregard positive results of blood cultures for P. putida as 
evidence of contaminants, and should perform supplemen- 
tal bacteriologic tests for complete identification of 
this organism if more than one blood culture finding is 
positive (6). 
There have been no reported cases of pneumonia caused 
by P. putida. In the case of infection described here, the 
patient was a healthy female with bronchiectasis and 
without a serious underlying disease. The clinical and 
pathophysiologic picture of this patient was compatible 
with bronchiectasis described recently (7). To obtain an 
aetiological diagnosis of pneumonia, protected specimen 
brush under fibre broncho-scope will be recommended. 
However, the authors believe that the present case was 
primary lung infection caused by mucoid P. putida, because 
sputum culture on admission exhibited pure and heavy 
growth of mucoid P. putida, and numerous neutrophils 
which had phagocytized the organism were observed on 
microscopic examination of sputum smears. 
Identification of Pseudomonas species was performed 
using the API 20NE microtube recognition system (8). It is 
important to remember that the other fluorescent 
Pseudomonas species should always be considered in the 
differential diagnosis if using the API 20NE microtube 
recognition system (6). However, in the present study, in 
addition to the API 20NE system, the failure to grow at 
42°C differentiates P. putida from P. aeruginosa, and 
the lack of gelatin hydrolysis and egg yolk reaction 
distinguishes P. putida from P. jhorescens (2). 
The isolated organism was resistant to a variety of 
antimicrobial drugs (cefotiam and aminoglycosides), but a 
clinical and bacteriologic cure was achieved with ceftazi- 
dime and minocycline. Among the currently available 
antibiotics tested, imipenem, piperacillin, carumonum 
and ceftazidime were active against P. putida, and new 
quinolones appear to be a promising agent on the basis of in 
liit~o results. Anaissie et al. reported that imipenem, ceftazi- 
dime and ciprofloxacin are effective against P. putida (6). It 
has also been reported that meropenem shows a good to 
moderate activity against P. putida (9). 
Stockley et al. reported that nebulized amoxicillin is 
effective to control chronic purulent bronchiectasis (10). As 
this patient experienced recurrent pneumonia, nebulization 
of antibiotics may be useful to prevent pneumonia. 
The case described here emphasizes that a mucoid 
strain of P. putida can be isolated from human clinical 
sources, and may cause pulmonary infection in an 
immunocompetent host. 
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Introduction Case 1 
In cystic fibrosis, (CF) the lungs are usually affected dif- 
fusely, but in some patients, focal disease may predominate 
(1). Aggressive medical therapy with intravenous antibiotics 
and chest physiotherapy is the first-line treatment, but in 
cases which fail to respond, surgical resection of the affected 
lobe has been advocated (2). We reviewed the clinical 
courses, up to 15 months post-operatively, of all three of 
our patients in whom this procedure had been undertaken. 
All patients had received prolonged intensive medical treat- 
ment without significant improvement in their clinical or 
radiological status prior to surgery. 
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A lo-year-old boy had persistent right upper lobe bron- 
chiectasis. His mean lung function tests (o/ predicted 
for height) preceding lobectomy, derived from all lung 
function results recorded over the year, were FEV, 
44% (SD 3.7%) and FVC 61% (SD 9.0%), and he required 
seven hospital admissions. During the post-operative 
year, his mean lung function tests improved, with FEV, 
48% (SD 6.4%) and FVC 68% (SD 9.6%): and he was 
admitted five times for treatment. One year post- 
operatively, his weight centile position was unchanged but 
his height centile position had improved; although he 
remained pre-pubertal. His chest X-ray Crispin Norman 
(CN) score had fallen from 28, pre-operatively, to 8 
(Plate 1). 
